EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the UK Myeloma Research Alliance risk profile in transplant‐ineligible multiple myeloma patients treated with novel agents

Hitomi Nakayama iD, Tomonori Nakazato iD, Atsushi Takahata iD, Eriko Sato iD, Maho Kawakami, Keigo Okada iD, Takashi Abe iD, Toshiaki Hayashi iD, Kohtaro Toyama iD, Yasutaka Senpuku, Masaru Nakagawa, Motoki Takano und 15 weitere

British Journal of Haematology · 2026-11 · 209 (5) · 2117-2126

DOI: 10.1111/bjh.70810 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 03.09.2026. Verfasst von Hitomi Nakayama und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant‐ineligible newly diagnosed MM (TIE‐NDMM) utilizing easily available clinical parameters. In this study, we evaluated the prognostic value of MRP in TIE‐NDMM patients treated with novel agents. We retrospectively analysed the data of 799 evaluable MM patients diagnosed between January 2011 and January 2023, extracted from the Japan Clinical Hematology Research Group‐EAST (J‐CHARGE)‐MM database. Overall survival (OS) differed significantly across the three MRP risk groups ( p < 0.01). The MRP risk groups remained independently prognostic when adjusted for treatment period and first‐line therapy (medium vs. low: hazard ratio [HR], 1.71; p < 0.01; high vs. low: HR, 2.61; p < 0.01). In subgroup analyses, the MRP classification significantly predicted OS in patients treated with bortezomib‐based and lenalidomide‐based regimens. However, there was no difference in OS between the MRP risk groups in patients treated with daratumumab‐based regimens. MRP is a robust prognostic tool for real‐world TIE‐NDMM patients treated with novel agents. Further studies are warranted to clarify its prognostic utility in the era of front‐line anti‐CD38 monoclonal antibody‐based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleAgedMalePrognosisLenalidomideAged, 80 and overAntibodies, MonoclonalBortezomibMiddle AgedUnited Kingdom

Stichwörter der Autor:innen

daratumumabgeriatricmultiple myelomamyeloma risk profileprognosis

Substanzen

LenalidomideAntibodies, MonoclonalBortezomibdaratumumab

Autor:innen und Institutionen

  • Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
  • Department of Hematology, Yokosuka Kyosai Hospital, Yokohama, Kanagawa, Japan.
  • Department of Hematology, Juntendo University Nerima Hospital, Nerima City, Tokyo, Japan.
  • Department of Hematology, Ome Medical Center, Ōme, Tokyo, Japan.
  • Department of Hematology, Niigata City General Hospital, Niigata, Niigata, Japan.
  • Department of Hematology, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.

ORCID-Profile: Hitomi Nakayama, Tomonori Nakazato, Atsushi Takahata, Eriko Sato, Keigo Okada, Takashi Abe, Toshiaki Hayashi, Kohtaro Toyama, Keisuke Tanaka, Yuki Osada, Junichi Watanabe, Michihide Tokuhira, Takayuki Ikezoe, Noriyoshi Iriyama, Katsuhiro Miura, Takashi Kumagai, Takehiko Mori

Zitieren

APA

Nakayama, H., Nakazato, T., Takahata, A., Sato, E., Kawakami, M., Okada, K., Abe, T., Hayashi, T., Toyama, K., Senpuku, Y., Nakagawa, M., Takano, M., Tanaka, K., Osada, Y., Watanabe, J., Yamamoto, K., Sekiguchi, Y., Oshikawa, G., Kimura, Y., …, & Mori, T. (2026). Evaluation of the UK Myeloma Research Alliance risk profile in transplant‐ineligible multiple myeloma patients treated with novel agents. British Journal of Haematology, 209(5), 2117-2126. https://doi.org/10.1111/bjh.70810

Vancouver

Nakayama H, Nakazato T, Takahata A, Sato E, Kawakami M, Okada K, et al. Evaluation of the UK Myeloma Research Alliance risk profile in transplant‐ineligible multiple myeloma patients treated with novel agents. British Journal of Haematology. 2026;209(5):2117-2126. doi:10.1111/bjh.70810

BibTeX
@article{Nakayama2026,
  author = {Nakayama, Hitomi and Nakazato, Tomonori and Takahata, Atsushi and Sato, Eriko and Kawakami, Maho and Okada, Keigo and Abe, Takashi and Hayashi, Toshiaki and Toyama, Kohtaro and Senpuku, Yasutaka and Nakagawa, Masaru and Takano, Motoki and Tanaka, Keisuke and Osada, Yuki and Watanabe, Junichi and Yamamoto, Koh and Sekiguchi, Yasunobu and Oshikawa, Gaku and Kimura, Yuta and Tokuhira, Michihide and Suzuki, Ken and Ikezoe, Takayuki and Iriyama, Noriyoshi and Miura, Katsuhiro and Kumagai, Takashi and Toyota, Shigeo and Mori, Takehiko},
  title = {Evaluation of the UK Myeloma Research Alliance risk profile in transplant‐ineligible multiple myeloma patients treated with novel agents},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2117--2126},
  doi = {10.1111/bjh.70810}
}
Kostenlos starten →